Chimeric Antigen Receptor News and Research

RSS

Could scorpion venom inspire new treatments for liver disease?

Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.3-blocking peptides and antiviral compounds as potential therapeutic leads, while emphasizing that limited hepatic efficacy data, poor pharmacokinetics, immunogenicity, and manufacturing challenges must be overcome before clinical translation.

8 Sep 2026

Tumor environments sculpt diverse natural killer cells for cancer therapies

For decades, natural killer (NK) cells have been classified into two main groups based on surface markers: one specialized for cytokine production and the other for direct killing.

4 Sep 2026

Scalable stem cell method advances off-the-shelf CAR-T therapies

Researchers at the Center for Regenerative Medicine (CReM) at Boston Medical Center (BMC) and Boston University (BU) have developed a scalable method for generating CD4+ helper T cells from induced pluripotent stem cells (iPSCs), overcoming a longstanding challenge in the development of stem cell-based immunotherapies.

27 Aug 2026

Gene removal makes engineered immune cells more effective against osteosarcoma

Scientists at St. Jude Children's Research Hospital have discovered that removing the gene for Regnase-1 from engineered immune cells makes them more effective at treating relapsed osteosarcoma.

25 Aug 2026

Genetic tool turns soft cancer cells into immune targets

Researchers at the USC Viterbi School of Engineering and Keck School of Medicine of USC have engineered a remarkable genetic tool that addresses one of the most persistent obstacles in cancer immunotherapy: the physical softness of tumors.

11 Aug 2026

Risk-adapted frameworks reshape pediatric neuroblastoma care

Neuroblastoma is the most common solid tumor outside the brain in children younger than five years old and accounts for about 15% of pediatric cancer deaths.

6 Aug 2026

Newly-discovered protein acts as off switch for human immune cells

Mayo Clinic researchers have identified a protein that cancer cells use to shut down the body's immune response, a discovery that could help scientists develop new treatments that make cancer immunotherapies more effective.

3 Aug 2026

Immature NK cells in donor cord blood can undermine CAR NK cell therapy activity

The composition of donor cord blood may play a critical role in the success of chimeric antigen receptor (CAR) natural killer (NK) cell therapies.

29 Jul 2026

Inherited genetics can influence safety and success of CAR-T cell therapy

Chimeric antigen receptor (CAR)-T cell therapy, which reprograms an individual's immune cells to seek out and destroy certain cancer cells, has revolutionized treatment for blood cancers such as lymphoma.

24 Jul 2026

MEK inhibition could limit T cell exhaustion and give a boost to immunotherapy

A major pillar of cancer immunotherapy involves stimulating T cells, the specialized killers of the immune system, to attack tumors.

23 Jul 2026

Novel leukemia therapy successfully eradicates measurable residual disease

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

7 Jul 2026

First-in-class experimental CAR T-cell therapy shows promise against solid tumors

Researchers with the Charbonneau Cancer Institute at the University of Calgary and McMaster University have identified a unique target present on a specific group of solid cancerous tumors.

2 Jul 2026

Reversing macrophage metabolism may improve cancer immunotherapy outcomes

Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the tumor microenvironment.

1 Jul 2026

Dual-target CAR-T therapy shows promise against aggressive brain tumors

Researchers at McMaster University have developed a new cancer immunotherapy strategy that can simultaneously attack deadly brain tumors and the immune cells that help them grow.

1 Jul 2026

Engineered CAR-T cells offer potential rheumatoid arthritis cure

For the 18 million people living with rheumatoid arthritis, disease management currently means a lifetime of injections-a reality that new research from Tsinghua University may soon begin to change.

22 Jun 2026

New method generates renewable supply of progenitor immune cells

In a paper published in Cell, a USC Stem Cell-led team reports a new way of generating a renewable and expandable supply of the progenitor cells that give rise to macrophages.

19 Jun 2026

Repurposed cancer therapy enables successful kidney transplantation

A pioneering clinical trial has successfully enabled three patients with end-stage kidney disease to receive previously improbable kidney transplants.

4 Jun 2026

Novel CAR T treatment makes previously impossible kidney transplants possible

A pioneering clinical trial has successfully enabled two patients with end-stage kidney disease to receive previously improbable kidney transplants.

3 Jun 2026

Pediatric experts reveal the 10 research areas set to shape child health

Pediatric research leaders identified 10 high-promise areas likely to shape child health over the next 5 to 10 years, including genomics, mental health, vaccines, artificial intelligence, perinatal medicine, precision therapeutics, health equity, nutrition, environmental health, and cancer treatment. The paper argues that these opportunities will only translate into better outcomes if pediatric research receives sustained funding, public trust, workforce support, advocacy, and equitable implementation.

1 Jun 2026

New guidelines for identifying and treating high-risk IEC-HS patients

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering durable responses for patients with otherwise refractory disease. However, its clinical success is accompanied by a spectrum of immune-related toxicities, which remain a major challenge in practice.

15 May 2026